You have free access to this content

Trends and projections of hepatitis C virus epidemiology in Latin America

  1. David Kershenobich1,
  2. Homie A. Razavi2,
  3. Juan Francisco Sánchez-Avila3,
  4. Fernando Bessone4,
  5. Henrique S. Coelho5,
  6. Lucy Dagher6,
  7. Fernando L. Gonçales7,
  8. Jorge F. Quiroz8,
  9. Federico Rodriguez-Perez9,
  10. Barbara Rosado10,
  11. Carolyn Wallace2,
  12. Francesco Negro11,
  13. Marcelo Silva12

Article first published online: 8 JUN 2011

DOI: 10.1111/j.1478-3231.2011.02538.x

Issue

Liver International

Liver International

Special Issue: The global health burden of hepatitis C virus infection

Volume 31, Issue Supplement s2, pages 18–29, July 2011

Additional Information

How to Cite

Kershenobich, D., Razavi, H. A., Sánchez-Avila, J. F., Bessone, F., Coelho, H. S., Dagher, L., Gonçales, F. L., Quiroz, J. F., Rodriguez-Perez, F., Rosado, B., Wallace, C., Negro, F. and Silva, M. (2011), Trends and projections of hepatitis C virus epidemiology in Latin America. Liver International, 31: 18–29. doi: 10.1111/j.1478-3231.2011.02538.x

Author Information

  1. 1

    Department of Experimental Medicine, School of Medicine, Universidad Nacional Autónoma de México (UNAM), Hospital General de Mexico, Mexico City, Mexico

  2. 2

    Center for Disease Analysis, Kromite, Louisville, CO, USA

  3. 3

    Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, México

  4. 4

    Gastroenterology and Hepatology Unit, University of Rosario School of Medicine, Rosario, Argentina

  5. 5

    Department of Clinical Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

  6. 6

    Policlínica Metropolitana, Caracas, Venezuela

  7. 7

    Grupo de Estudo das Hepatites, Disciplina de Doenças Infecciosas, Departamento de Clínica Médica, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, UNICAMP, São Paulo, Brazil

  8. 8

    Servicio de Gastroenterologia del Hospital Guillermo Almenara Irigoyen, Lima, Peru

  9. 9

    Gastroenterology Department, VA Caribbean Healthcare System, San Juan, Puerto Rico

  10. 10

    Ponce School of Medicine, Ponce, Puerto Rico

  11. 11

    Services de Gastroenterologie et d'Hepatologie et de Pathologie Clinique, Hopitaux Universitaires, Genève, Switzerland

  12. 12

    Liver and Clinical Research Units, Hospital Universitario Austral, Buenos Aires, Argentina

*Correspondence Homie Razavi, Center for Disease Analysis, Kromite, 901 Front Street, Suite 291, Louisville, CO 80027, USA Tel: +1 720 890 4848 Fax: +1 303 552 9119 E-mail: hrazavi@kromite.com

Publication History

  1. Issue published online: 8 JUN 2011
  2. Article first published online: 8 JUN 2011
  3. Submitted: 27 March 2011, Accepted: 1 April 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (432K)

Reference

  • 1
    Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362: 2095–100.
  • 2
    El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745–50.
  • 3
    Boyer JL, Chang EB, Collyar DE, Deleve LD, et al. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002; 36: S1–S20.
  • 4
    Kershenobich D, Razavi HA, Cooper CL, et al. Applying a system approach to forecast the total HCV-infected population size-Model validation using US data. Liver Int 2011; 31(Suppl. 2): 4–17.
  • 5
    Chiquete E, Panduro A. Low prevalence of anti-hepatitis C virus antibodies in Mexico: A systematic review. Intervirology 2007; 50: 1–8.
  • 6
    Abdel-Hamid M, El-Daly M, El-Kafrawy S, et al. Comparison of second- and third-generation enzyme immunoassays for detecting antibodies to hepatitis C virus. J Clin Microbiol 2002; 40: 1656–9.
  • 7
    IMS Health. IMS National Prescription Audit. July 27 2009. Available at http://www.imshealth.com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid=734eeec5accb2210VgnVCM100000ed152ca2RCRDdvgnextfmt=default.
  • 8
    McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580–93.
  • 9
    Jacobson IM, Brown RS Jr, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007; 46: 971–81.
  • 10
    Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705–14.
  • 11
    Fay O, Gonzalez J, Rey J. Blood donors and general population. Acta Gastroenterol Latinoam 2005; 35: S11–S12.
  • 12
    Picchio GR, Bare PC, Descalzi VI, et al. High prevalence of infection with a single hepatitis C virus genotype in a small rural community of Argentina. Liver Int 2006; 26: 660–5.
    Direct Link:
  • 13
    Remesar M, Gamba C, Kuperman S, et al. Antibodies to hepatitis C and other viral markers in multi-transfused patients from Argentina. J Clin Virol 2005; 34 (Suppl. 2): S20–S26.
  • 14
    Weissenbacher M, Rossi D, Radulich G, et al. High seroprevalence of bloodborne viruses among street-recruited injection drug users from Buenos Aires, Argentina. Clin Infect Dis 2003; 37 (Suppl. 5): S348–S352.
  • 15
    Golemba MD, Di Lello FA, Bessone F, et al. High prevalence of hepatitis C virus genotype 1b infection in a small town of Argentina. Phylogenetic and Bayesian coalescent analysis. PLoS One 2010; 5: e8751.
  • 16
    Insua JT, O'Flaherty M, Frontera Vacca MJ, et al. HCV infection (HCVI) prevalence in Argentine and impact of unsafe health care parenteral practices (HC-UPP): a seroprevalence survey. Society of General Internal Medicine 28th Annual Meeting, New Orleans, LA, 11–14 May 2005. New Orleans, LA, USA: Society of General Internal Medicine. Journal of General Internal Medicine, 20(Suppl. 2): 185.
  • 17
    Ridruejo E, Adrover R, Cocozzella D, Fernandez N, Reggiardo MV. Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon-Ribavirin in daily practice. Ann Hepatol 2010; 9: 46–51.
  • 18
    [Epidemiology of viral hepatitis in Argentina] Epidemiologia de hepatitis virales en Argentina. Servicio Hepatitis y Gastroenteritis Departamento Virologia Laboratorio Nacional de Referencia Instituto Nacional de Enfermedades Infecciosas (INEI) Administracion Nacional de Laboratorios e Institutos de Salud (ANLIS) ‘Dr Carlos Gregorio Malbran’ 2009. Available at http://www.slidefinder.net/E/EpidHVenArgentinaSiNaVE/3629031 (accessed 6 January 2010).
  • 19
    Re V, Lampe E, Yoshida CF, et al. Hepatitis C virus genotypes in Cordoba, Argentina. Unexpected high prevalence of genotype 2. Medicina (B Aires) 2003; 63: 205–10.
  • 20
    Oubina JR, Quarleri JF, Rudzinski M, et al. Genomic characterization of hepatitis C virus isolates from Argentina. J Med Virol 1995; 47: 97–104.
    Direct Link:
  • 21
    Cruz JR. Supply of blood for transfusion in the Caribbean and Latin American countries in 2006–2007: progress since 2005 of the regional plan for transfusion safety. Washington, DC: Pan American Health Organization, 2009.
  • 22
    Sookoian S, Castano G, Castiglioni T, et al. The problem of hepatitis C virus infection in blood donors. Clinico-epidemiological, virological and histological evaluation. Medicina (B Aires) 1997; 57: 699–707.
  • 23
    Fassio E, Schroder T. Statement of the Argentinian Concensus on Hepatitis C 2007. Acta Gastroenterol Latinoam 2008; 38: 56–74.
  • 24
    Fainboim H, Gonzalez J, Fassio E, et al. Prevalence of hepatitis viruses in an anti-human immunodeficiency virus-positive population from Argentina. A multicentre study. J Viral Hepatol 1999; 6: 53–7.
    Direct Link:
  • 25
    Perez Bianco R, Santarelli MT. Analysis of a national serological survey for diseases transmitted by blood transfusion. Medicina (B Aires) 1993; 53: 491–6.
  • 26
    Cruz JR. Transfusion medicine in the Caribbean countries, 2000. Washington, DC: Pan American Health Organization, 2002.
  • 27
    Cruz JR. Medicina transfusional en los países del Caribe y Latinoamérica, 2000–2003. [Transfusion medicine in the Caribbean and Latin American Countries, 2001–2003]. Washington, DC: Organización Panamericana de la Salud, 2005.
  • 28
    Quarleri JF, Robertson BH, Mathet VL, et al. Genomic and phylogenetic analysis of hepatitis C virus isolates from Argentine patients: a six-year retrospective study. J Clin Microbiol 2000; 38: 4560–8.
  • 29
    Gismondi MI, Turazza EI, Grinstein S, Galoppo MC, Preciado MV. Hepatitis C virus infection in infants and children from Argentina. J Clin Microbiol 2004; 42: 1199–202.
  • 30
    Quarleri JF, Robertson BH, Mathet V, et al. Genomic and phylogenetic analysis of hepatitis C virus strains from Argentina. Medicina (B Aires) 1998; 58: 153–9.
  • 31
    Bessone F, Daruich J, Lupo S, et al. Hepatitis C viral load is increased and related to genotype 1 in HCV+/HIV+co-infection compared with HCV+non-coinfected patients. Abstract # 598. Hepatology 2003; 38: 449A.
  • 32
    Gismondi MI, Preciado MV, Badia I, et al. Genotype characterization of hepatitis C virus infection in children. Medicina (B Aires) 2001; 61: 815–20.
  • 33
    Di Lello F, Garcia G, Kott V, Sookoian S, Campos R. Diversity of hepatitis C virus genotype 1b in Buenos Aires, Argentina: description of a new cluster associated with response to treatment. J Med Virol 2008; 80: 619–27.
  • 34
    Parana R, Vitvitski L, Pereira JE. Hepatotropic viruses in the Brazilian Amazon: a health threat. Braz J Infect Dis 2008; 12: 253–6.
  • 35
    Guia de vigilância epidemiológica (Guide to epidemiology surveillance), 7th ed. Brasil: Ministerio da Saude. Secretaria de Vigilancia em Saude. Departamento de DST A e H V pp. 23–46.
  • 36
    Clinical guidelines for hepatitis C 2007, Dispoe sobre Protocolo Clínico e Diretrizes Terapêuticas para Hepatite Viral C. 2007. Report No.: Portaria No. 34, de 28 de Setembro de 2007; ID606503-0. Brasil: Ministério da Saúde. Secretaria de Vigilancia em Saude. Departamento de DST AeHVPNpaPeoCdHV.
  • 37
    Toledo AC Jr, Greco DB, Felga M, et al. Seroprevalence of hepatitis B and C in Brazilian army conscripts in 2002: a cross-sectional study. Braz J Infect Dis 2005; 9: 374–83.
  • 38
    Silva L, Parana R, Mota E, et al. Prevalence of hepatitis C virus in urban and rural populations of northeast Brazil-pilot study. Arq Gastroenterol 1995; 32: 168–71.
  • 39
    Cavalheiro NP, Barone AA, Tengan FM. HCV serotypes in Brazilian patients. Int J Infect Dis 2002; 6: 228–32.
  • 40
    Brandao AB, Fuchs SC. Risk factors for hepatitis C virus infection among blood donors in southern Brazil: a case-control study. BMC Gastroenterol 2002; 2: 18.
  • 41
    Silva GF, Nishimura NF, Coelho KI, Soares EC. Grading and staging chronic hepatitis C and its relation to genotypes and epidemiological factors in Brazilian blood donors. Braz J Infect Dis 2005; 9: 142–9.
  • 42
    Miranda AE, Figueiredo NC, Schmidt R, Page-Shafer K. A population-based survey of the prevalence of HIV, syphilis, hepatitis B and hepatitis C infections, and associated risk factors among young women in Vitoria, Brazil. AIDS Behav 2008; 12: S25–S31.
  • 43
    Almeida D, Tavares-Neto J, Vitvitski L, et al. Serological markers of hepatitis A, B and C viruses in rural communities of the semiarid Brazilian northeast. Braz J Infect Dis 2006; 10: 317–21.
  • 44
    Martins RM, Porto SO, Vanderborght BO, et al. Short report: prevalence of hepatitis C viral antibody among Brazilian children, adolescents, and street youths. Am J Trop Med Hyg 1995; 53: 654–5.
  • 45
    Silva GF, Coelho KI, Nishimura NF, Soares EC. Progression of liver fibrosis in blood donors infected with hepatitis C virus. Rom J Gastroenterol 2004; 13: 291–7.
  • 46
    Focaccia R, Baraldo DC, Ferraz ML, et al. Demographic and anthropometrical analysis and genotype distribution of chronic hepatitis C patients treated in public and private reference centers in Brazil. Braz J Infect Dis 2004; 8: 348–55.
  • 47
    Focaccia R, da Conceicao OJ, Sette H Jr, et al. Estimated prevalence of viral hepatitis in the general population of the municipality of Sao Paulo, measured by a serologic survey of a stratified, randomized and residence-based population. Braz J Infect Dis 1998; 2: 269–84.
  • 48
    Zarife MA, Silva LK, Silva MB, et al. Prevalence of hepatitis C virus infection in north-eastern Brazil: a population-based study. Trans R Soc Trop Med Hyg 2006; 100: 663–8.
  • 49
    Brazil. Health Ministry. Health Surveillance Secretary. Department of STDs, AaVH, Brasil. Ministerio da Saude.Secretaria de Vigilancia em Saude. Departamento de DST, AeHV. [Viral hepatitis in numbers]. Brazil Minsitry of Health Department of STDs, AIDS and Viral Hepatitis 2010. Available at http://www.aids.gov.br/pagina/hepatites-virais-em-numeros (accessed 9 December 2010).
  • 50
    Aquino JA, Pegado KA, Barros LP, Machado LF. Seroprevalence of hepatitis B virus and hepatitis C virus infections among individuals in the State of Para. Rev Soc Bras Med Trop 2008; 41: 334–7.
  • 51
    United Nations: World population prospects: revision Population database ed. United Nations, New York, NY, USA.
  • 52
    Parolin MB, Russo AA, de Almeida PT, Baldanzi GR, Lopes RW. Multicenter study on the prevalence of hepatitis C virus infection in blood donors in the city of Curitiba, Brazil. Arq Gastroenterol 1999; 36: 117–21.
  • 53
    Paltanin LF, Reiche EM. Seroprevalence of anti-hepatitis C virus antibodies among blood donors, Brazil. Rev Saude Publica 2002; 36: 393–9.
  • 54
    Rosini N, Mousse D, Spada C, Treitinger A. Seroprevalence of HbsAg, Anti-HBc and anti-HCV in Southern Brazil, 1999-2001. Braz J Infect Dis 2003; 7: 262–7.
  • 55
    da Fonseca JC, Brasil LM. Hepatitis C virus infection in the Amazon Brazilian region. Rev Soc Bras Med Trop 2004; 37 (Suppl. 2): 1–8.
  • 56
    Valente VB, Covas DT, Passos AD. Hepatitis B and C serologic markers in blood donors of the Ribeirao Preto Blood Center. Rev Soc Bras Med Trop 2005; 38: 488–92.
  • 57
    de Santana NP, de Freitas LA, Lyra AC, et al. Liver histological alterations in patients with chronic hepatitis C and normal ALT levels in the city of Salvador, Northeast-Brazil. Braz J Infect Dis 2005; 9: 134–41.
  • 58
    Andrade AF, Oliveira-Silva M, Silva SG, Motta IJ, Bonvicino CR. Seroprevalence of hepatitis B and C virus markers among blood donors in Rio de Janeiro, Brazil, 1998–2005. Mem Inst Oswaldo Cruz 2006; 101: 673–6.
  • 59
    Nascimento MC, Mayaud P, Sabino EC, Torres KL, Franceschi S. Prevalence of hepatitis B and C serological markers among first-time blood donors in Brazil: a multi-center serosurvey. J Med Virol 2008; 80: 53–7.
  • 60
    Perone C, Del Castillo DM, Pereira GL, et al. High prevalence of genotype 1 in individuals with hepatitis C in Belo Horizonte, MG. Rev Soc Bras Med Trop 2008; 41: 238–42.
  • 61
    Silva CM, Costi C, Krug LP, et al. High proportion of hepatitis C virus genotypes 1 and 3 in a large cohort of patients from Southern Brazil. Mem Inst Oswaldo Cruz 2007; 102: 867–70.
  • 62
    Martins RM, Teles SA, Freitas NR, et al. Distribution of hepatitis C virus genotypes among blood donors from mid-west region of Brazil. Rev Inst Med Trop Sao Paulo 2006; 48: 53–5.
  • 63
    Amorim RM, Oliveira CP, Wyant PS, et al. Hepatitis C virus genotypes in blood donors from the Federal District, Central Brazil. Mem Inst Oswaldo Cruz 2004; 99: 895–7.
  • 64
    Vogler IH, Nishiya A, Morimoto HK, et al. Serological, epidemiological and molecular aspects of hepatitis C virus infection in a population from Londrina, PR, Brazil, 2001–2002. Rev Inst Med Trop Sao Paulo 2004; 46: 303–8.
  • 65
    Campiotto S, Pinho JR, Carrilho FJ, et al. Geographic distribution of hepatitis C virus genotypes in Brazil. Braz J Med Biol Res 2005; 38: 41–9.
  • 66
    Pereira LM, Spinelli V, Ximenes RA, et al. Chronic hepatitis C infection: influence of the viral load, genotypes, and GBV-C/HGV coinfection on the severity of the disease in a Brazilian population. J Med Virol 2002; 67: 27–32.
  • 67
    Silva LK, Parana R, Souza SP, et al. Hepatitis C virus genotypes in a northeastern area of Brazil. Am J Trop Med Hyg 2000; 62: 257–60.
  • 68
    Oliveira ML, Bastos FI, Sabino RR, et al. Distribution of HCV genotypes among different exposure categories in Brazil. Braz J Med Biol Res 1999; 32: 279–82.
  • 69
    Parana R, Vitvitski L, Berby F, et al. HCV infection in northeastern Brazil: unexpected high prevalence of genotype 3a and absence of African genotypes. Arq Gastroenterol 2000; 37: 213–6.
  • 70
    Krug LP, Lunge VR, Ikuta N, et al. Hepatitis C virus genotypes in Southern Brazil. Braz J Med Biol Res 1996; 29: 1629–32.
  • 71
    Brasil.Ministerio da Saude.Secretaria de Vigilancia em Saude.Departamento de DST AeHV. [Hepatitis C-Distribution of confirmed cases in Brazil by region, 1980-2005]. Brasil Ministério da Saúde Secretaria de Vigilancia em Saude Departamento de DST,Aids e Hepatites Virais 2010. Available at http://portal.saude.gov.br/portal/arquivos/pdf/hepatite_C_2006.pdf.
  • 72
    Brasil. Ministerio da Saude, Secretaria de Vigilancia em Saude, Departamento de DST AeHV. [Hepatitis, by region/by state and year, Brazil, from 1999 to 2007. Tables and graphs]. Brasil Ministério da Saúde Secretaria de Vigilancia em Saude Departamento de DST, Aids e Hepatites Virais 2009. Available at http://portal.saude.gov.br/portal/arquivos/pdf/situacao_epidemiologica.pdf.
  • 73
    Valdespino JL, Conde-González CJ, Olaiz-Fernández G, et al. Seroprevalence of hepatitis C among Mexican adults: an emerging public health problem? Salud pública Méx 2007; 49: s395–s403.
  • 74
    Vera de Leon L, Juarez Navarro JA, Diaz Gomez M, et al. Epidemiologic and situational panorama of hepatitis C in Mexico. Rev Gastroenterol Mex 2005; 70: 25–32.
  • 75
    Rivas-Estilla AM, Cordero-Perez P, Trujillo-Murillo Kdel C, et al. Genotyping of hepatitis C virus (HCV) in infected patients from Northeast Mexico. Ann Hepatol 2008; 7: 144–7.
  • 76
    Garcia-Montalvo BM. Seropositivity of HIV, HBV, HCV and Treponema pallidum in blood donors in southeast Mexico. Rev Invest Clin 2006; 58: 567–72.
  • 77
    Benitez-Arvizu G, Cortez-Gomez R, Novelo-Garza BA, et al. Prevalence of hepatitis C virus in the blood bank at Centro Medico Nacional La Raza. Rev Med Inst Mex Seguro Soc 2006; 44: 227–33.
  • 78
    Chiquete E, Sanchez LV, Becerra G, et al. Performance of the serologic and molecular screening of blood donations for the hepatitis B and C viruses in a Mexican Transfusion Center. Ann Hepatol 2005; 4: 275–8.
  • 79
    Carreto-Velez MA, Carrada-Bravo T, Martinez-Magdaleno A. Seroprevalence of HBV, HCV, and HIV among blood donors in Irapuato, Mexico. Salud Publica Mex 2003; 45 (Suppl. 5): S690–S693.
  • 80
    Ladron-de Guevara L, Gomez N, Vazquez-Cantarell M, Garcia-Mendez S, Di Silvio M. Prevalence of and risk factors for hepatitis C in blood donors. Rev Gastroenterol Mex 2002; 67: 11–6.
  • 81
    Alvarez-Munoz MT, Vences-Aviles MA, Damacio L, et al. Hepatitis C virus RNA (HCV-RNA) in blood donors and family members seropositive for anti-HCV antibodies. Arch Med Res 2001; 32: 442–5.
  • 82
    Mendez-Sanchez N, Baptista-Gonzalez H, Sanchez-Gomez RH, Bordes-Aznar J, Uribe-Esquivel M. The prevalence of hepatitis B and C in blood donors in a 3rd-level hospital of Mexico City. Salud Publica Mex 1999; 41: 475–8.
  • 83
    Ayala Gaytan JJ, Guerra Avalos FJ, Moro Brondo P, Casillas Romo A. Prevalence of viral markers for hepatitis B, C and human immunodeficiency virus in volunteer blood donors in Northeast Mexico. Rev Gastroenterol Mex 1997; 62: 250–3.
  • 84
    Pita-Ramirez L, Torres-Ortiz GE. Prevalence of viral antibodies and syphilis serology in blood donors from a hospital. Rev Invest Clin 1997; 49: 475–80.
  • 85
    Islas S, Yamaguchi K, Nishimura Y, et al. Antibody to hepatitis C virus in volunteer blood donors of the Hospital de Especialidades, National Medical Center, Mexico City. Arch Med Res 1994; 25: 361–2.
  • 86
    Merino-Conde E, Orozco JA, Rojo-Medina J, Tovar A. Prevalence of hepatitis C virus among candidates for blood donation at the Hospital General de Mexico. In Vivo 1994; 8: 621–3.
  • 87
    Hernandez-Perez RE, Frias-Salcedo JA, Del Angel-Guevara O. The seroprevalence of antibodies against the hepatitis C virus in blood donors at the Hospital Central Militar. Salud Publica Mex 1994; 36: 538–40.
  • 88
    Cervantes Bustamante R, Ramirez Mayans JA, Jiron CR, et al. Prevalence of antibodies against hepatitis C virus (HCV) in a population of Mexican children. Acta Gastroenterol Latinoam 1996; 26: 301–3.
  • 89
    Mendez-Sanchez N, Ponciano-Rodriguez G, Chavez-Tapia NC, et al. Prevalence of hepatitis C infection in a population of asymptomatic people in a checkup unit in Mexico city. Dig Dis Sci 2005; 50: 733–7.
  • 90
    Santos-Lopez G, Sosa-Jurado F, Vallejo-Ruiz V, Melendez-Mena D, Reyes-Leyva J. Prevalence of hepatitis C virus in the Mexican population: a systematic review. J Infect 2008; 56: 281–90.
  • 91
    Dehesa-Violante M, Bosques-Padilla F, Kershenobich-Stalnikowitz D. Prevalence of hepatitis C virus genotypes in Mexican patients. Rev Gastroenterol Mex 2007; 72: 344–8.
  • 92
    Jimenez-Mendez R, Uribe-Salas F, Lopez-Guillen P, Cisneros-Garza L, Castaneda-Hernandez G. Distribution of HCV genotypes and HCV RNA viral load in different regions of Mexico. Ann Hepatol 2010; 9: 33–9.
  • 93
    Perez CM, Marrero E, Melendez M, et al. Seroepidemiology of viral hepatitis, HIV and herpes simplex type 2 in the household population aged 21–64 years in Puerto Rico. BMC Infect Dis 2010; 10: 76.
  • 94
    Rodriguez-Perez F, Suarez-Perez E, Alvarez-Rohena M, Toro DH. Prevalence of chronic hepatitis C virus genotypes among patients between 21 to 65 years old in Puerto Rico. P R Health Sci J 2004; 23: 49–56.
  • 95
    Reyes JC, Colon HM, Robles RR, et al. Prevalence and correlates of hepatitis C virus infection among street-recruited injection drug users in San Juan, Puerto Rico. J Urban Health 2006; 83: 1105–13.
  • 96
    Lopez-Navedo PJ, Lebron-Rivera R, Gonzalez-Trapaga J, et al. Prevalence of hepatitis C virus infection at three hemodialysis units in the western region of Puerto Rico. Bol Asoc Med P R 1999; 91: 100–2.
  • 97
    Sanchez LP, Flynn JM, Mayol M. Seroprevalence of blood borne transmissible diseases in trauma orthopaedic surgical patients. P R Health Sci J 1998; 17: 113–6.
  • 98
    Deseda CC, Sweeney PA, Woodruff BA, et al. Prevalence of hepatitis B, hepatitis C, and human immunodeficiency virus infection among women attending prenatal clinics in San Juan, Puerto Rico, from 1989-1990. Obstet Gynecol 1995; 85: 75–8.
  • 99
    Perez CM, Suarez E, Torres EA, Roman K, Colon V. Seroprevalence of hepatitis C virus and associated risk behaviours: a population-based study in San Juan, Puerto Rico. Int J Epidemiol 2005; 34: 593–9.
  • 100
    Colon HM, Robles RR, Deren S, et al. Between-city variation in frequency of injection among Puerto Rican injection drug users: East Harlem, New York, and Bayamon, Puerto Rico. J Acquir Immune Defic Syndr 2001; 27: 405–13.
  • 101
    Deren S, Oliver-Velez D, Finlinson A, et al. Integrating qualitative and quantitative methods: comparing HIV-related risk behaviors among Puerto Rican drug users in Puerto Rico and New York. Subst Use Misuse 2003; 38: 1–24.
  • 102
    Deren S, Robles R, Andia J, et al. Trends in HIV seroprevalence and needle sharing among Puerto Rican drug injectors in Puerto Rico and New York: 1992–1999. J Acquir Immune Defic Syndr 2001; 26: 164–9.
  • 103
    Ferrandiz QJ, Paz V, Cabrera C, et al. Guillermo Almenara Irigoyen State Hospital, Lima, Peru. Perfil epidemiológico y clínico de la hepatitis crónica C en el Hospital Guillermo Almenara Irigoyen, 2004, Lima-Peru, Conversation with: Razavi HA, Center for Disease Analysis, Kromite, Louisville, Colorado, USA, 2010.
  • 104
    de Los Rios R, Bussalleu A, Hurtado A, et al. Prevalence of anti hepatitis C antibodies in patients with chronic renal failure receiving conservative therapy. Rev Gastroenterol Peru 2006; 26: 265–70.
  • 105
    Mendez Chacon P, Vidalon A, Vildosola H. Risk factors for hepatitis C in hemodialysis and its impact on the waiting list for kidney transplantation. Rev Gastroenterol Peru 2005; 25: 12–8.
  • 106
    Colichon Yerosh A, Figueroa R, Moreno A, et al. Serologic prevalence of HCV antibodies in health personnel in Peru. Rev Gastroenterol Peru 2004; 24: 13–20.
  • 107
    Valdivia JA, Rivera S, Ramirez D, et al. Hepatitis C virus infection in female sexual workers from northern Lima. Rev Gastroenterol Peru 2003; 23: 265–8.
  • 108
    Diaz Diaz CT. Seroepidemiological study of heaptitis C in hemodialysis. Lima, Peru: Universidad Nacional Mayer de San Marcos (Lima), Faculty of Medicine Graduate School, 2002.
  • 109
    Sanchez JL, Sjogren MH, Callahan JD, et al. Hepatitis C in Peru: risk factors for infection, potential iatrogenic transmission, and genotype distribution. Am J Trop Med Hyg 2000; 63: 242–8.
  • 110
    Farfan G, Cabezas C. Prevalence of viral hepatitis type C in blood donors in Peru. Rev Gastroenterol Peru 2003; 23: 171–6.
  • 111
    Ferrandiz J, Colaretta M, Barreda C, et al. Genotipo predominante del virus hepatitis C en el Peru. Peru: Revista de Gastroenterolgia del Peru, 2000.
  • 112
    Monsalve-Castillo F, Costa L, Callejas-V , et al. Incidencia del virus de hepatitis c en etnias Yukpas y Bari de La Sierra de Perijá. Estado Zulia. Venezuela. Sociedad Venezolana de Microbiología 2005. Available at http://caibco.ucv.ve/caibco/vitae/VitaeVeinticinco/JornadaMicrobiologia/ArchivosHTML/VI-013.pdf
  • 113
    Cuadra-Sanchez C, Moronta-Pinango R, Cordova-Villanueva E, et al. Seroprevalence of hepatitis C virus (HCV) in patients of the Regional Viral Reference Laboratory (Maracaibo, Venezuela). Rev Gastroenterol Peru 2005; 25: 248–53.
  • 114
    Rojas N, Sanchez D, Rodriguez J. Seroprevalence of anti-VHC, coexistence of Ag-HBs, anti-HBc and HIV and a risk factor anti-VHC donors. Postgrad Med Bull 2003; XIX No.1: 9–17.
  • 115
    Monsalve-Castillo F, Gomez-Gamboa L, Albillos A, et al. [Hepatitis C virus in populations at risk for infection. Venezuela]. Rev Esp Enferm Dig 2007; 99: 315–9.
  • 116
    Fortes MdP, Trompiz A, Canonico Y, Vargas-Lovelle B, Machado IV. Hepatitis C virus genotype 1 frequency has not varied in Venezuela. Rev Colomb Gastroenterol 2009; 24: 256–8.
  • 117
    Pujol FH, Loureiro CL. Replacement of hepatitis C virus genotype 1b by genotype 2 over a 10-year period in Venezuela. J Clin Gastroenterol 2007; 41: 518–20.
  • 118
    Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010; 14: 1–21.
  • 119
    Mendez-Sanchez N, Gutierrez-Grobe Y, Kobashi-Margain RA. Epidemiology of HCV infection in Latin America. Ann Hepatol 2010; 9 (Suppl.): 27–9.
  • 120
    Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3: 41–6.
  • 121
    Robinson JW, Rosas M, Guzman F, Patarroyo ME, Moreno A. Comparison of prevalence of anti-hepatitis C virus antibodies in differing South American populations. J Med Virol 1996; 50: 188–92.
    Direct Link:
  • 122
    Cristina J. Genetic diversity and evolution of hepatitis C virus in the Latin American region. J Clin Virol 2005; 34 (Suppl. 2): S1–S7.
View Full Article (HTML) Get PDF (432K)